MyCelx Technologies Corporation — Director's Dealing 2021

Apr 13, 2021

National Storage Mechanism | Additional information

RNS Number : 3352V

MyCelx Technologies Corporation

13 April 2021

13 April 2021

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

Grant of Options

The Company announces the grant of share options over the Company's common shares of US$0.025 each ("Common Shares") under the 2011 MYCELX Omnibus Performance Incentive Plan which was extended at the 2019 Annual Meeting (the "Plan").

Details of the awards to Directors and a PDMR on 12 April 2021 together with their current beneficial holding of Common Shares are presented in the following below:

Grant of Share Options to Chief Financial Officer

Name	Number of share options granted	Exercise price	Total number of share options held following this notification	Total number of share options as % of current issued share capital
Kimberly Slayton	140,000	US$0.69*	270,000	1.39%

Ms. Slayton holds no Common Shares in the issued capital of the Company.

Grant of Share Options to President and Chief Science Officer

Name	Number of share options granted	Exercise price	Total number of share options held following this notification	Total number of share options as % of current issued share capital
Haluk Alper	70,000	US$0.69*	124,339	0.64%

In addition, following this award, Mr. Alper continues to be interested in 1,262,046 Common Shares, representing 6.49 per cent of the present issued capital of the Company.

Grant of Share Options to Chief Executive Officer

Name	Number of share options granted	Exercise price	Total number of share options held following this notification	Total number of share options as % of current issued share capital
Connie Mixon	210,000	US$0.69*	413,017	2.12%

In addition, following this award, Connie Mixon continues to be interested in 2,480,469 Common Shares, representing 12.76 per cent of the present issued capital of the Company.

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

The above grants formed part of wider grants of, in aggregate, 769,000 options to employees across the Company, on the same date, representing 3.95% of the current issued share capital. 

These share options granted on 12 April 2021 will vest as to one third equally on 12 April 2021, 12 April 2022 and 12 April 2023, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

Following the above grants, a total of 2,038,338 share options have been granted to directors and employees and are currently outstanding, representing 10.48% of the issued share capital of 19,443,750 Common Shares.

*Based on the closing mid-market price of the Company's Common Shares at 12 April 2021, and the closing US/£ exchange rate at that date.

For further information please contact:

MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO	Tel: +1 888 306 6843
Canaccord Genuity, Nominated Adviser Henry Fitzgerald-O'Connor Georgina McCooke	Tel: + 44 20 7523 8000
Celicourt Mark Antelme Jimmy Lea	Tel: +44 20 8434 2754

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

Notification of transactions of persons discharging managerial responsibility or connected persons

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Connie Mixon

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of US$0.025

USU624551078

b)

Nature of the transaction

Grant of share option to Connie Mixon under the MYCELX Omnibus Performance Incentive Plan

c)

Price(s) and volume(s)

Price(s)	Volume(s)
US$0.69	210,000

d)

Aggregated information

- Aggregated volume

- Price

n/a

n/a

e)

Date of the transaction

12/04/2021

f)

Place of the transaction

Grant of the options occurred outside a trading venue.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Kimberly Slayton

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of US$0.025

USU624551078

b)

Nature of the transaction

Grant of share option to Kimberly Slayton under the MYCELX Omnibus Performance Incentive Plan

c)

Price(s) and volume(s)

Price(s)	Volume(s)
US$0.69	140,000

d)

Aggregated information

- Aggregated volume

- Price

n/a

n/a

e)

Date of the transaction

12/04/2021

f)

Place of the transaction

Grant of the options occurred outside a trading venue.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Haluk Alper

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of US$0.025

USU624551078

b)

Nature of the transaction

Grant of share option to Haluk Alper under the MYCELX Omnibus Performance Incentive Plan

c)

Price(s) and volume(s)

Price(s)	Volume(s)
US$0.69	70,000

d)

Aggregated information

- Aggregated volume

- Price

n/a

n/a

e)

Date of the transaction

12/04/2021

f)

Place of the transaction

Grant of the options occurred outside a trading venue.

Notes to Editors

Through its revolutionary oil-free water technology, MYCELX brings its customers material benefits in terms of performance enhancement, cost savings and significantly improved environmental footprints. Working beyond any ordinary filtration methods, MYCELX's proprietary technology achieves oil removal to less than one part per million.  MYCELX supports leading international customers across the oil & gas value chain, as well as other industrial users.   MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

For more information, visit www.MYCELX.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFSFSSIVLIL